Genomics and the second golden era of cancer drug development

Mol Biosyst. 2005 May;1(1):17-26. doi: 10.1039/b501751n.

Abstract

The first golden era of cancer drug development was initiated in the 1940s and gave rise to the cytotoxic agents that dominate current cancer medicine. The second golden era is now underway in which cancer genomics will direct drug development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Drug Design*
  • Genomics
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors